Private Capital's LGND Position Overview
Private Capital (via Private Capital Management, LLC) currently holds 208,891 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $39.5 M, representing 3.62% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 7 quarters.
Based on 13F filings, Private Capital has maintained this position in LGND for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 81,128 shares. Largest reduction occurred in Q4 2025, reducing 18,267 shares.
Analysis based on 13F filings available since 2013 Q2
Private Capital's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Private Capital
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -18,267 | Reduce 8.04% | 208,891 | $189.07 |
| Q3 2025 | -2,095 | Reduce 0.91% | 227,158 | $177.14 |
| Q2 2025 | +81,128 | Add 54.77% | 229,253 | $113.68 |
| Q1 2025 | +14,435 | Add 10.80% | 148,125 | $104.93 |
| Q4 2024 | -190 | Reduce 0.14% | 133,690 | $107.15 |
| Q3 2024 | -625 | Reduce 0.46% | 133,880 | $100.09 |
| Q2 2024 | +134,505 | New Buy | 134,505 | $84.26 |
Private Capital's Ligand Pharmaceuticals Incorporated Investment FAQs
Private Capital first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q2 2024, acquiring 134,505 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Private Capital has held Ligand Pharmaceuticals Incorporated (LGND) for 7 quarters since Q2 2024.
Private Capital's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q2 2024, adding 134,505 shares worth $11.33 M.
According to the latest 13F filing for Q4 2025, Private Capital's firm, Private Capital Management, LLC, owns 208,891 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $39.5 M.
As of the Q4 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 3.62% of Private Capital's publicly disclosed stock portfolio, making it one of their key holdings.
Private Capital's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 229,253 shares, as reported at the end of Q2 2025.